336 F. Supp. 3d 395
D.N.J.2018Background
- End-Payor Plaintiffs (EPPs) — insurers, Taft‑Hartley funds, municipalities, and individuals — allege Pfizer and Ranbaxy conspired to delay generic entry of Lipitor, causing overpayments.
- Core factual allegations: Pfizer procured a later ‘995 enantiomer patent through allegedly fraudulent data, listed it in the Orange Book, pursued sham litigation and a sham citizen petition, and entered a reverse‑payment settlement with Ranbaxy delaying generic entry until late 2011.
- EPPs bring state‑law antitrust and consumer‑protection claims on behalf of a multistate putative class (many states listed); damages alleged arise from March 24, 2010 forward.
- Defendants moved for judgment on the pleadings under Rule 12(c) on grounds including federal patent/FDA preemption, failure to satisfy state pre‑suit notice or class‑action prohibitions, Illinois Brick standing limitations, and failure to plead state consumer‑protection elements.
- The Court denied preemption dismissal, found several state notice and class‑action statutory limits applicable (dismissing some claims without prejudice), dismissed some state claims with prejudice (Illinois, Rhode Island antitrust; Illinois and Maine consumer claims), and dismissed portions of monopolization claims in Kansas, New York, and Tennessee to the extent based on Pfizer’s unilateral conduct.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Federal patent/FDA preemption of state claims | EPPs: claims are antitrust/consumer‑protection based and therefore not preempted by patent or FDA law | Defs: claims necessarily depend on patent validity/enforcement or interfere with FDA authority and are preempted | Court: denied preemption — followed Third Circuit in In re Lipitor; state claims survive because they include elements distinct from patent law and citizen‑petition allegations are independent of patent validity or Buckman preemption |
| State pre‑filing notice requirements (AZ, HI, NV, UT, MA, WV) | EPPs: Rule 23 or federal procedure should govern; notice not required at pleading | Defs: statutes require notice to state AG or pre‑suit demand as substantive prerequisites | Court: statutory notice provisions apply; EPPs’ class claims under those states dismissed without prejudice; leave to amend to plead compliance |
| State statutory class‑action bars (MT, TN, UT, etc.) vs Rule 23 | EPPs: Shady Grove means Rule 23 controls in federal court | Defs: those state bars are substantive limits on remedies and survive in federal court | Court: applies Justice Stevens’ Shady Grove approach; class bars enforceable — class claims in those states dismissed without prejudice or must be limited to individual named plaintiffs |
| Illinois Brick/standing under state antitrust laws (IL, RI, UT) | EPPs: Rule 23 or state repealers permit indirect purchaser class claims | Defs: Illinois & Rhode Island law bar indirect purchaser class suits; Utah requires a Utah resident plaintiff and pre‑suit notice | Court: Illinois antitrust and related Illinois consumer claims dismissed with prejudice (no indirect purchaser class); Rhode Island antitrust dismissed with prejudice (repealer not retroactive); Utah antitrust dismissed without prejudice (no named Utah plaintiff; may amend) |
| Requirement of concerted action under certain state antitrust statutes (KS, NY, TN) | EPPs: Count I aggregates conduct and includes reverse settlement with Ranbaxy; should survive | Defs: those statutes require concerted action; Pfizer’s unilateral acts (patent procurement, Orange Book listing, citizen petition) cannot support monopolization/conspiracy claims | Court: dismissed Count I allegations to the extent they rest on Pfizer’s unilateral conduct (patent procurement, listing, reissuance, sham petition/litigation); claims based on the reverse settlement with Ranbaxy survive |
| State consumer‑protection pleading sufficiency (CA, IL, ME, NE, NV, NM, NY, NC, RI) | EPPs: alleged fraudulent/unfair acts, price‑inflation and consumer harm suffice | Defs: many states require reliance, consumer nexus, inducement, or other specific elements not pleaded | Court: denied dismissal for CA, NE, NV, NM, NY, NC (claims adequately pled); granted dismissal without leave for IL and ME consumer claims; RI consumer claims dismissed with leave to amend narrowly (natural‑person requirement) |
Key Cases Cited
- In re Lipitor Antitrust Litig., 855 F.3d 126 (3d Cir. 2017) (state antitrust/consumer claims do not necessarily arise under federal patent law)
- In re Wellbutrin XL Antitrust Litig., 868 F.3d 132 (3d Cir. 2017) (analyzing antitrust standing for reverse‑payment claims and the “but‑for” causation inquiry)
- Buckman Co. v. Plaintiffs’ Legal Committee, 531 U.S. 341 (2001) (fraud‑on‑FDA claims can be preempted where they would conflict with federal regulatory scheme)
- Shady Grove Orthopedic Assocs. v. Allstate Ins. Co., 559 U.S. 393 (2010) (Rule 23 versus state law class‑action limits; plurality and concurrence outline different tests)
- Dow Chem. Co. v. Exxon Corp., 139 F.3d 1470 (Fed. Cir. 1998) (state unfair‑competition claims not preempted when they contain additional elements distinct from patent law)
- Walker Process Equip., Inc. v. Food Mach. & Chem. Corp., 382 U.S. 172 (1965) (fraudulent procurement of patents can support antitrust liability)
- Christianson v. Colt Indus. Operating Corp., 486 U.S. 800 (1988) (well‑pleaded complaint rule for determining when a claim arises under federal patent law)
- Ashcroft v. Iqbal, 556 U.S. 662 (2009) (plausibility pleading standard)